H.C. Wainwright Reaffirms Their Buy Rating on Sangamo Biosciences (SGMO)

By Ryan Adsit

H.C. Wainwright analyst Debjit Chattopadhyay reiterated a Buy rating on Sangamo Biosciences (SGMOResearch Report) today and set a price target of $16.00. The company’s shares closed last Monday at $8.53.

According to TipRanks.com, Chattopadhyay is a 3-star analyst with an average return of 2.1% and a 39.0% success rate. Chattopadhyay covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Precision BioSciences, and Sarepta Therapeutics.

Currently, the analyst consensus on Sangamo Biosciences is a Moderate Buy with an average price target of $13.50.

See today’s analyst top recommended stocks >>

Based on Sangamo Biosciences’ latest earnings release for the quarter ending December 31, the company reported a quarterly net profit of $4.56 million. In comparison, last year the company had a GAAP net loss of $18.66 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Sangamo Therapeutics, Inc. engages in researching and developing transcription factors in the regulation of genes. It focuses on the research, development and commercialization of engineered DNA-binding proteins for therapeutic genome editing and gene regulation technology platform is enabled by the engineering of a class of transcription factors known as zinc finger DNA-binding proteins. The company was founded by Edward O. Lanphier II in 1995 and is headquartered in Richmond, CA.